Novo Ventures invests millions in Bavarian Nordic rival
London-based biotech company Reviral has raised USD 55 million for the continued development of its phase II candidate against the respiratory disease RSV. Novo Ventures is among the investors.
BY MIKKEL AABENHUS HEMMINGSEN
The competition is intensifying on the potential billion-dollar market for treatment of the respiratory disease RSV and now, Novo Holdings also sets the ball rolling.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
